TY - JOUR
T1 - Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer
AU - Connolly, Denise C.
AU - Bao, Rudi
AU - Nikitin, Alexander Yu
AU - Stephens, Kasie C.
AU - Poole, Timothy W.
AU - Hua, Xiang
AU - Harris, Skye S.
AU - Vanderhyden, Barbara C.
AU - Hamilton, Thomas C.
PY - 2003/3/15
Y1 - 2003/3/15
N2 - In women, >80% of malignant ovarian tumors are of epithelial origin. Early detection of these tumors is very challenging, and extensive i.p. dissemination is common by the time of diagnosis. The lack of adequate genetic mouse models of ovarian carcinomas significantly delays advances in early detection and treatment. We report that female transgenic mice expressing the transforming region of SV40 under control of the Mullerian inhibitory substance type II receptor gene promoter develop bilateral ovarian tumors in ∼50% of cases. Histologically, these tumors are poorly differentiated carcinomas with occasional cysts and papillary structures present at the surface of the ovary. These tumors disseminate i.p., invade omentum, and form ascites as do human ovarian carcinomas. The epithelial origin of these tumors is supported by detection of cytokeratins 8 and 19, and the absence of α-inhibin, a protein characteristically expressed in normal granulosa cells and most granulosa cell tumors. Cell lines derived from the ascites exhibit the properties of epithelial ovarian cancer, such as anchorage-independent growth, tumorigenicity in immunocompromised mice, expression of epithelial cell markers, and organotropic implantation. The availability of a transgenic mouse model of disseminated ovarian carcinoma and respective cell lines should advance our understanding of this neoplasm, and serve as a useful tool for the evaluation of emerging detection and treatment strategies.
AB - In women, >80% of malignant ovarian tumors are of epithelial origin. Early detection of these tumors is very challenging, and extensive i.p. dissemination is common by the time of diagnosis. The lack of adequate genetic mouse models of ovarian carcinomas significantly delays advances in early detection and treatment. We report that female transgenic mice expressing the transforming region of SV40 under control of the Mullerian inhibitory substance type II receptor gene promoter develop bilateral ovarian tumors in ∼50% of cases. Histologically, these tumors are poorly differentiated carcinomas with occasional cysts and papillary structures present at the surface of the ovary. These tumors disseminate i.p., invade omentum, and form ascites as do human ovarian carcinomas. The epithelial origin of these tumors is supported by detection of cytokeratins 8 and 19, and the absence of α-inhibin, a protein characteristically expressed in normal granulosa cells and most granulosa cell tumors. Cell lines derived from the ascites exhibit the properties of epithelial ovarian cancer, such as anchorage-independent growth, tumorigenicity in immunocompromised mice, expression of epithelial cell markers, and organotropic implantation. The availability of a transgenic mouse model of disseminated ovarian carcinoma and respective cell lines should advance our understanding of this neoplasm, and serve as a useful tool for the evaluation of emerging detection and treatment strategies.
KW - Animals
KW - Antigens, Polyomavirus Transforming/biosynthesis
KW - Chimera/genetics
KW - Disease Models, Animal
KW - Epithelium/metabolism
KW - Female
KW - Humans
KW - Immunohistochemistry
KW - Mice
KW - Mice, Inbred C57BL
KW - Mice, Transgenic
KW - Ovarian Neoplasms/genetics
KW - Pregnancy
KW - Promoter Regions, Genetic
KW - Receptors, Peptide/biosynthesis
KW - Receptors, Transforming Growth Factor beta
KW - Regulatory Sequences, Nucleic Acid
KW - Reverse Transcriptase Polymerase Chain Reaction
KW - Transfection
KW - Tumor Cells, Cultured
UR - http://www.scopus.com/inward/record.url?scp=0037444396&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000181702300038&DestLinkType=FullRecord&DestApp=WOS
M3 - Article
C2 - 12649204
SN - 0008-5472
VL - 63
SP - 1389
EP - 1397
JO - Cancer Research
JF - Cancer Research
IS - 6
ER -